Q3 2025 Ionis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ionis Pharmaceuticals Inc (IONS) reported strong momentum with the launch of TRYNGOLZA, the only FDA-approved treatment for familial chylomicronemia syndrome (FCS), and raised its 2025 financial guidance.
- The company achieved European approval for TRYNGOLZA, with plans for its partner, Sobi, to begin distribution in Europe in the fourth quarter.
- FDA approval of DAWNZERA for hereditary angioedema (HAE) marked Ionis Pharmaceuticals Inc (IONS)'s second independent launch, with strong early adoption and positive feedback from physicians and patients.
- Positive topline results from pivotal programs, including olezarsen for severe hypertriglyceridemia (sHTG) and zilganersen for Alexander Disease, position Ionis Pharmaceuticals Inc (IONS) for additional independent launches next year.
- Ionis Pharmaceuticals Inc (IONS) anticipates four key launches from its partnered pipeline by the end of 2027, targeting both rare and highly prevalent life-threatening diseases, which will expand the impact of its discovered medicines and increase total revenue.
- Despite strong performance, the vast majority of the estimated 3,000 people living with FCS in the US remain unidentified, indicating a need for continued focus on patient finding efforts.
- The company faces challenges in expanding its reach to additional prescribers for sHTG patients, requiring significant investment in commercial infrastructure and payer engagement.
- Ionis Pharmaceuticals Inc (IONS) anticipates an operating loss between $275 million and $300 million for the full year, despite improved guidance.
- The launch of DAWNZERA is expected to provide only a modest revenue contribution this year, with a greater impact anticipated next year.
- There are uncertainties regarding pricing dynamics and payer engagement for olezarsen in the sHTG market, which could impact its commercial success.
Good morning and welcome to the Ionis third-quarter 2025 financial results conference call. And as a reminder, this call is being recorded.
At this time, I would like to turn the conference over to Mr. Wade Walke, Senior Vice President of Investor Relations to lead off the call. Please begin, sir.
Thank you, Chuck.
Before we begin, I encourage everyone to go to the investor section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call.
With me on the call this morning are Brett Monia, our Chief Executive Officer; Richard Geary, our Chief Development Officer; Kyle Jenne, our Chief Global Product Strategy Officer, and Beth Hougen, our Chief Financial Officer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
